Please assess the completion status of the following clinical trial:

Trial Title: Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* Inclusion Criteria:~  1. Patients being treated with SU as 1st line treatment according to the approved therapeutic indication.~ 2. Histologically confirmed diagnosis of mRCC (clear cell RCC as well as nonclear cell RCC) with measurable disease according to RECIST 1.1~ 3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.~     Exclusion Criteria:~  <!-- -->~  1. Patients being treated with cytokines or any other treatment other than SU in 1st line setting~ 2. Patients presenting with a known hypersensitivity to SU or its metabolites will not be included in the study per the label.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).